UT gets federal stimulus grant for Parkinson's disease research

June 25, 2009

The University of Texas Health Science Center at Houston has received a $412,500 federal stimulus grant for Parkinson's disease research, the university announced today. It is the university's first federal stimulus grant.

Parkinson's disease is an incurable brain disorder. Its symptoms include trembling, stiffness and problems with balance. An estimated one million Americans are diagnosed with the neurological disorder.

The two-year grant will support efforts by researchers in the university's Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases (IMM) to develop a therapeutic vaccine.

Rowen Chang, Ph.D, an IMM professor of protein chemistry, is the principal investigator on the grant that comes from The National Institute of Neurological Disorders and Stroke through the American Recovery and Reinvestment Act of 2009. Chuantao Jiang, M.D., Ph.D., an assistant research professor at the IMM, is co-principal investigator.

Chang plans to add one or two researchers to the team of scientists in his lab with the funds. The grant extends through April 30, 2011.

"We are excited about receiving this grant, which will support our research and help the economy by employing more scientists," Chang said.

Chang believes he may be able to slow the progression of Parkinson's disease and possibly even prevent it by targeting a protein associated with the disease called alpha-synuclein.

If successful, Chang's vaccine would work by strengthening the immune system's ability to suppress the activity of alpha-synuclein through the production of antibodies. The effectiveness of this vaccine will be tested in transgenic mice expressing human alpha-synuclein.

The American Recovery and Reinvestment Act was passed by Congress to jumpstart the economy and create jobs.

"The focus of the research has been on creating 'locked structures' of proteins by internal cross linking," said C. Thomas Caskey, M.D., IMM Director/CEO. "The application of this technology to creation of therapeutic antibodies for Parkinson's disease is a creative approach to new therapies for a challenging disease."
Chang has been on the faculty of the Institute of Molecular Medicine for about a decade and was one of the initial appointments. He obtained his master's of science degree from the National Taiwan University in Taipei and his doctorate from the Australian National University at Canberra.

University of Texas Health Science Center at Houston

Related Antibodies Articles from Brightsurf:

Scientist develops new way to test for COVID-19 antibodies
New research details how a cell-free test rapidly detects COVID-19 neutralizing antibodies and could aid in vaccine testing and drug discovery efforts.

Mussels connect antibodies to treat cancer
POSTECH research team develops innovative local anticancer immunotherapy technology using mussel protein.

For an effective COVID vaccine, look beyond antibodies to T-cells
Most vaccine developers are aiming solely for a robust antibody response against the SARS-CoV-2 virus, despite evidence that antibodies are not the body's primary protective response to infection by coronaviruses, says Marc Hellerstein of UC Berkeley.

Children can have COVID-19 antibodies and virus in their system simultaneously
With many questions remaining around how children spread COVID-19, Children's National Hospital researchers set out to improve the understanding of how long it takes pediatric patients with the virus to clear it from their systems, and at what point they start to make antibodies that work against the coronavirus.

The behavior of therapeutic antibodies in immunotherapy
Since the late 1990s, immunotherapy has been the frontline treatment against lymphomas where synthetic antibodies are used to stop the proliferation of cancerous white blood cells.

Re-engineering antibodies for COVID-19
Catholic University of America researcher uses 'in silico' analysis to fast-track passive immunity

Seroprevalence of antibodies to SARS-CoV-2 in 10 US sites
This study estimates how common SARS-CoV-2 antibodies are in convenience samples from 10 geographic sites in the United States.

Neutralizing antibodies in the battle against COVID-19
An important line of defense against SARS-CoV-2 is the formation of neutralizing antibodies.

Three new studies identify neutralizing antibodies against SARS-CoV-2
A trio of papers describes several newly discovered human antibodies that target the SARS-CoV-2 virus, isolated from survivors of SARS-CoV-2 and SARS-CoV infection.

More effective human antibodies possible with chicken cells
Antibodies for potential use as medicines can be made rapidly in chicken cells grown in laboratories.

Read More: Antibodies News and Antibodies Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.